Vendor Intelligence Report: Marvel Pep

Published 13 Jun 2026. 17-page investigative report on who is behind Marvel Pep: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 11 Finnrick lab tests, Marvel Pep’s overall pass rate is 100%: 11 pass and 0 fail. The signal is strong but narrow: every Finnrick sample is Retatrutide, not a cross-catalog record. Retatrutide tests well under purity-focused grading, while the certificate review shifts the caveat to fill control and traceability, including underfill/overfill outliers, missing batch IDs, and no-label shipments; ratings look less robust under stricter methodology.

The corporate record points away from the site’s established-manufacturer posture. A .cn WHOIS record ties the brand cluster to a Xiamen sole-proprietor trading firm, while the retail domain, Facebook footprint, and empty Wayback history fit a late-2025 public launch. That chronology conflicts with the retail/B2B longevity claims, and the claimed Wichita address resolves as a residential placeholder reused across WoodMart-template sites.

Other trust signals are similarly uneven: the About page retains cosmetics-demo language and an unsubstantiated Google-review count, the retail/wholesale surfaces use multiple emails and WhatsApp numbers, and the non-Retatrutide catalog has no Finnrick product-specific support. The affiliate scan found no X, coupon-site, or web-Reddit promoter network, but the highest product-level concern is a direct-to-consumer Botulinum toxin listing without documented licensed dispensing or cold-chain controls.

Inside the full report:

  • Retatrutide testing narrative, methodology-divergence charts, and Appendix A laboratory data
  • WHOIS and domain chronology for marvelpep.com, marvel-peptide.com, and marvelpeptide.cn
  • Chinese entity trail and the registry-access limits around owner-level verification
  • WoodMart template, fake-review, and Wichita-address analysis
  • Retail/wholesale contact-map across emails, WhatsApp numbers, Facebook pages, and sales names
  • Payment-rail, regulatory-check, and affiliate-scan findings with caveats

Risk assessment

  • Corporate-identity deception and recourse risk — high: All products: fabricated U.S. address, unsupported “over ten years” / “7 years” claims, template review text, and true-operator evidence pointing to a China-linked sole proprietorship.
  • Botulinum toxin direct-to-consumer sale risk — high: Botulinum toxin 100 IU: listed through a gray-market catalog with no documented licensed dispensing, cold-chain verification, or medical oversight.
  • Retatrutide fill-accuracy risk — medium: Retatrutide: 11/11 Finnrick tests pass and current rating is 89.2%, but field certificate review documented 12.0% underfill and 8.5% overfill extremes.
  • Retatrutide batch-traceability risk — medium: Retatrutide: 4 of 11 tested submissions lacked batch IDs; no-label/no-batch shipments impair adverse-event tracing and lot-level recall.
  • Non-Retatrutide verification gap — medium: Semaglutide, Tirzepatide, Cagrilin, BPC-157, CJC-1295, DSIP, Epithalon, Cerebrolysin, ARA-290, AOD9604, BB10, and similar catalog items have no Finnrick tests in the supplied record.